MJA
MJA

The Australian Lupus Registry and Biobank: a timely initiative

Med J Aust 2017; 206 (5): 194-195. || doi: 10.5694/mja16.01282

A collaborative effort to provide real world evidence for therapies for patients with lupus

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse clinical manifestations, which places an unacceptable level of burden on affected patients. Australian data on lupus are scarce, with figures suggesting a prevalence of SLE that ranges from 19 per 100 000 in people of European ancestry to 92 per 100 000 in Indigenous Australians,1 similar to other chronic diseases such as hepatitis C.2 Survival rates for SLE patients in the 1950s were as low as 50% at 5 years. With improvements in the treatment of renal disease and infection, survival rates in most studies improved to around 90% at 10 years by the 1990s. However, it is still a sobering thought that SLE, which typically presents in women in their second or third decade of life, confers a 1 in 10 chance of dying before the age of 40.3 Damage accumulation, long term medication side effects (particularly steroids side effects), fatigue and uncertainty profoundly affect quality of life.4 Fundamental data regarding age, geographic and ethnic distribution; natural history of the disease; currently used treatments; and unmet needs of patients in Australia have not been well defined.

Please login with your free MJA account to view this article in full

  • Sean O'Neill1
  • Eric F Morand2
  • Alberta Hoi2

  • 1 Liverpool Hospital, Sydney, NSW
  • 2 Monash University, Melbourne, VIC

Correspondence: sean.oneill@unsw.edu.au

Acknowledgements: 

We thank our funding sponsors, including MOVE Muscle, Bone and Joint Health; GlaxoSmithKline; UCB and AstraZeneca, patient participants and members of the Australian Lupus Registry and Biobank.

Competing interests:

No relevant disclosures.

  • 1. Nikpour M, Bridge JA, Richter S. A systematic review of prevalence, disease characteristics and management of systemic lupus erythematosus in Australia: identifying areas of unmet need. Intern Med J 2014; 44: 1170-1179.
  • 2. Dore GJ, Law M, MacDonald M, Kaldor JM. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 2003; 26: 171-184.
  • 3. Mak A, Cheung MW, Chiew HJ, et al. Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum 2012; 41: 830-839.
  • 4. Sutanto B, Singh-Grewal D, McNeil HP, et al. Experiences and perspectives of adults living with systemic lupus erythematosus: thematic synthesis of qualitative studies. Arthritis Care Res 2013; 65: 1752-1765.
  • 5. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-2127.
  • 6. Bookman AAM, Urowitz MB, Koehler BE, et al. The Bimodal pattern of mortality in systemic lupus erythematosus (SLE). J Rheumatol 1974; 1: 57.
  • 7. Lu LJ, Wallace DJ, Navarra SV, Weisman MH. Lupus registries: evolution and challenges. Semin Arthritis Rheum 2010; 39: 224-245.
  • 8. Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016; 75: 1615-1621.
  • 9. Yap KS, Northcott M, Hoi ABY, et al. Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort. Lupus Sci Med 2015; 2: e000064.
  • 10. Croyle L, Hoi A, Morand EF. Characteristics of azathioprine use and cessation in a longitudinal lupus cohort. Lupus Sci Med 2015; 2: e000105.
  • 11. Connelly KL, Kandane-Rathnayake R, Hoi A, et al. Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus. Sci Rep 2016; 6: 29909.
  • 12. Antony A, Kandane-Rathnayake RK, Ko T, et al. Validation of the Lupus Impact Tracker in an Australian patient cohort. Lupus 2017; 26: 98-105.
  • 13. Goldblatt F, O’Neill SG. Clinical aspects of autoimmune rheumatic diseases. Lancet 2013; 382: 797-808.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article